Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?

Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.

Zacks Investment Research • Feb 10, 2026

Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?

The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Feb 9, 2026

Goldman Sachs Just Upgraded These 3 Stocks to a Buy Rating

Goldman initiated a buy rating on Biohaven targeting its IgAN treatment in an over $40B U.S. market.

24/7 Wall Street • Feb 9, 2026

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the urine (hematuria), deep reductions in proteinuria, and improvement in fatigue and kidney function (eGFR) within weeks.

PRNewsWire • Jan 12, 2026

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Jan 7, 2026

Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial

Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal of a phase 2 trial.

Schaeffers Research • Dec 26, 2025

Biohaven Misses The Mark In Depression Trial, Stock Falls

On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).

Benzinga • Dec 26, 2025

US Stocks Mixed; Biohaven Shares Fall

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.1% on Friday.

Benzinga • Dec 26, 2025

Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise

BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Opakalim for depression and Taldefgrobep alfa for SMA missed primary endpoints. Current cash runway is approximately 3.1 quarters, heightening urgency for successful near-term clinical milestones and FDA approvals.

Seeking Alpha • Dec 26, 2025

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus

U.S. stock futures slipped on Friday after Wednesday's higher close. Futures of major benchmark indices fell.

Benzinga • Dec 26, 2025